R&D Trends

NIH partners with 11 biopharmaceutical companies on cancer immunotherapy strategies

Friday, October 13, 2017

The NIH and 11 biopharmaceutical companies launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers—standardized biological markers of disease and treatment response—to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role. 

[Read More]

Karyopharm, Ono ink $193M deal

Friday, October 13, 2017

Karyopharm Therapeutics and Ono Pharmaceutical announced their entry into an exclusive license agreement for the development and commercialization of selinexor, Karyopharm’s lead, novel, oral Selective Inhibitor of Nuclear Export (SINE) compound, and KPT-8602, Karyopharm’s second-generation oral SINE compound. The agreement includes the development of selinexor and KPT-8602 for the diagnosis, treatment and/or prevention of all human oncology indications in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries (the Territory).

[Read More]

Stand Up To Cancer awards Moffitt $2.67M to study lung cancer immunotherapy

Friday, October 13, 2017

Moffitt Cancer Center was awarded a $2.67 million grant from Stand Up To Cancer (SU2C) to study a possible new immunotherapy for non-small cell lung cancer. This is one of 10 first-of-its-kind grants being awarded by the SU2C Catalyst program. Under the program, pharmaceutical companies donate funds to support collaborative team research using products provided by the companies, such as compounds and agents in development or approved for investigational use. The Moffitt study will be in partnership with Bristol-Myers Squibb, with additional assistance from Iovance and Prometheus Laboratories.

[Read More]

LEO Science & Tech Hub, Elektrofi collaborate on dermatological drug delivery

Wednesday, October 11, 2017

LEO Science & Tech Hub, an R&D unit of LEO Pharma dedicated to identifying, developing, and funding innovative solutions that improve the lives of people with skin diseases, announced a collaboration agreement with Elektrofi, a Cambridge-based biotechnology company focused on drug delivery innovations, to explore advanced formulation technology for dermatological drug delivery. 

[Read More]

Children’s Hospital Los Angeles to study “Bubble Boy” syndrome

Tuesday, October 10, 2017

Michael Pulsipher, M.D., of the Children’s Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles, along with co-principal investigator, Sung-Yun Pai, M.D., of Boston Children’s Hospital, has been awarded nearly $9 million from the National Institute of Allergy and Infectious Diseases of the NIH to study a new treatment approach for babies born with severe combined immunodeficiency (SCID), which prevents the immune system from functioning normally. In a multi-site study, investigators plan to determine the lowest dose of chemotherapy needed for babies with SCID undergoing bone marrow transplant—the standard treatment for SCID. The goal is to restore the immune system safely and effectively with less toxicity than the higher dose regimens currently in use.

[Read More]

NIH to fund seven research centers in minority institutions

Tuesday, October 10, 2017

The National Institute on Minority Health and Health Disparities (NIMHD), part of the NIH, will fund seven new awards to support the Research Centers in Minority Institutions (RCMI) Specialized Centers program. RCMI is designed to support institutional research capacity and foster the career development of new and early career investigators conducting minority health and health disparities research. The centers will share approximately $122 million over five years, pending available funds.

[Read More]

NIH to fund Centers of Excellence on Minority Health and Health Disparities

Tuesday, October 10, 2017

Twelve specialized research centers designed to conduct multidisciplinary research, research training and community engagement activities focused on improving minority health and reducing health disparities will launch. The centers, to be funded by the National Institute on Minority Health and Health Disparities (NIMHD), part of the NIH, will share approximately $82 million over five years, pending the availability of funds.

[Read More]